. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Guidance in the United States and United Kingdom has included cognitive behavior therapy for psychosis (CBTp) as a preferred therapy. But recent advances have widened the CBTp targets to other symptoms and have different methods of provision, eg, in groups. AIM: To explore the effect sizes of current CBTp trials including targeted and nontargeted symptoms, modes of action, and effect of methodological rigor. METHOD: Thirty-four CBTp trials with data in the public domain were used as source data for a meta-analysis and investigation of the effects of trial methodology using the Clinical Trial Assessment Measure (CTAM). RESULTS: There were overall beneficial effects for the target symptom (33 studies; effect size = 0.400 [95% confidence interval [CI] = 0.252, 0.548]) as well as significant effects for positive symptoms (32 studies), negative symptoms (23 studies), functioning (15 studies), mood (13 studies), and social anxiety (2 studies) with effects ranging from 0.35 to 0.44. However, there was no effect on hopelessness. Improvements in one domain were correlated with improvements in others. Trials in which raters were aware of group allocation had an inflated effect size of approximately 50%-100%. But rigorous CBTp studies showed benefit (estimated effect size = 0.223; 95% CI = 0.017, 0.428) although the lower end of the CI should be noted. Secondary outcomes (eg, negative symptoms) were also affected such that in the group of methodologically adequate studies the effect sizes were not significant. CONCLUSIONS: As in other meta-analyses, CBTp had beneficial effect on positive symptoms. However, psychological treatment trials that make no attempt to mask the group allocation are likely to have inflated effect sizes. Evidence considered for psychological treatment guidance should take into account specific methodological detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The primary outcome was change in positive symptom severity at the end of treatment and at follow-up”
From A systematic review and meta-analysis of cognitive behavioural informed psychological interventions for psychiatric inpatients with psychosis (2020) · cites this paper as Wykes et al., 2008
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combining medication with evidence-based psychotherapy produces clinically significant improvement over medications alone for severe depression and psychotic disorders.9,10”
From Acceptance-based Behavior Therapy for Depression With Psychosis (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychological therapies have demonstrated to be effective for patients experiencing psychotic symptoms (1, 2) and are recommended by treatment guidelines already in the acute illness and treatment phase (3, 4).”
From Developing a mechanism-based therapy for acute psychiatric inpatients with psychotic symptoms: an Intervention Mapping approach (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is limited evidence supporting the use of pharmacological and psychological interventions for depression in the context of schizophrenia (Whitehead et al. 2002; Wykes et al., 2008).”
From Acceptance and Commitment Therapy for depression following psychosis: An examination of clinically significant change (2015) · cites this paper as Wykes et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although effective at treating positive symptoms, Cognitive Behavioural Therapy for psychosis (CBTp) is less effective for treating emotional dysfunction associated with psychosis such as depression, hopelessness and suicide risk (Birchwood, 2003; Wykes et al., 2008; Tarrier et al., 2006).”
From Acceptance and Commitment Therapy for depression following psychosis: An examination of clinically significant change (2015) · cites this paper as Wykes et al., 2008
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cognitive behaviour therapy for schizophrenia
Jones, C., Cormac, I., Silveira da Mota Neto, J. I., & Campbell, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000524.pub2 · Cited by 269
RetractedAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“In addition, concurrent validity was assessed within an initial 22 studies by correlation with the scores from 3 other scales devised to assess methodological rigor.(42,43,52) The correlations of these scales with the CTAM scores on the corpus of CBTp data were as follows: CTAM and Jadad, q = .”
MethodZhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
The Handbook of Research Synthesis.
Howel, D., Cooper, H., & Hedges, L. V. (1995) · Biometrics · doi:10.2307/2533295 · Cited by 3,642
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560 · cited 1×
“For instance, poorer quality masking of allocation of treatments has been shown to be associated with up to 40% increased estimate of benefit in circulatory and digestive diseases, mental health, obstetrics, and childbirth.(36,37)”
BackgroundAssessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Influence of Family Life on the Course of Schizophrenic Disorders: A Replication
Brown, G. W., Birley, J. L. T., & Wing, J. K. (1972) · British Journal of Psychiatry · doi:10.1192/bjp.121.3.241 · Cited by 1,770 · cited 1×
“High CTAM 0.084 � 0.154, 0.322 9.21 ( 5 ), not significant 6 685 0.048, 1.144 Low CTAM 0.680 0.174, 1.186 32.96 (8), significant at the 5% level 9 268”
InfluentialA method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349 · cited 1×
“In addition, concurrent validity was assessed within an initial 22 studies by correlation with the scores from 3 other scales devised to assess methodological rigor.(42,43,52) The correlations of these scales with the CTAM scores on the corpus of CBTp data were as follows: CTAM and Jadad, q = .”
MethodExpressed Emotion and Psychiatric Relapse: A Meta-analysis
Butzlaff, R. L., & Hooley, J. M. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.6.547 · Cited by 1,310
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105 · cited 1×
“High CTAM 0.147 � 0.172, 0.466 8.49 (4), not significant 5 347 � 0.058, 0.782 Low CTAM 0.509 0.221, 0.797 23.04 ( 9 ), significant at the 5% level 10 520”
InfluentialPILLING, S., BEBBINGTON, P., KUIPERS, E., GARETY, P., GEDDES, J., ORBACH, G., & MORGAN, C. (2002) · Psychological Medicine · doi:10.1017/s0033291702005895 · Cited by 887 · cited 1×
“High CTAM 0.206 � 0.104, 0.516 28.33 (8), significant at the 5% level 9 631 � 0.100, 0.908 Low CTAM 0.610 0.200, 1.020 83.33 ( 13 ), significant at the 5% level 14 637”
InfluentialMarshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757 · cited 1×
“This therapy has also been considered in the Schizophrenia Patient Outcome Report Team guidance in the United States and has been recommended.(25)”
BackgroundSensky, T., Turkington, D., Kingdon, D., Scott, J. L., Scott, J., Siddle, R., O'Carroll, M., & Barnes, T. R. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.165 · Cited by 693
Incorporating variations in the quality of individual randomized trials into meta-analysis
Detsky, A. S., Naylor, C. D., O'Rourke, K., McGeer, A. J., & L'Abbé, K. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90085-2 · Cited by 640
Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S. W., Moring, J., O’Brien, R., Schofield, N., & McGovern, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1706 · Cited by 536
Self-citationRandomised controlled trial of compliance therapy: 18-month follow-up
Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.172.5.413 · Cited by 520
Self-citationBalk, E. M. (2002) · JAMA · doi:10.1001/jama.287.22.2973 · Cited by 478 · cited 1×
“Some assessments of trial quality have been found seriously to affect the assessment of treatment effectiveness in other areas of treatment.(90) However, in our assessments, no specific domain dominated.”
BackgroundKuipers, E., Garety, P., Fowler, D., Dunn, G., Bebbington, P., Freeman, D., & Hadley, C. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.4.319 · Cited by 455
Tarrier, N., Beckett, R., Harwood, S., Baker, A., Yusupoff, L., & Ugarteburu, I. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.4.524 · Cited by 454
Self-citationTarrier, N., Yusupoff, L., Kinney, C., McCarthy, E., Gledhill, A., Haddock, G., & Morris, J. (1998) · BMJ · doi:10.1136/bmj.317.7154.303 · Cited by 442
Self-citationGaudiano, B. A., & Herbert, J. D. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.02.007 · Cited by 435
Drury, V., Birchwood, M., Cochrane, R., & MacMillan, F. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.593 · Cited by 407
Efficacy of Psychological Therapy in Schizophrenia: Conclusions From Meta-analyses
Pfammatter, M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl030 · Cited by 401 · cited 1×
“High CTAM 0.223 0.017, 0.428 27.73 (11), significant at the 5% level 12 1124 0.038, 0.584 Low CTAM 0.534 0.343, 0.725 35.35 ( 20 ), significant at the 5% level 21 840”
InfluentialQuality of Reporting of Randomized Trials as a Measure of Methodologic Quality
Huwiler-Müntener, K. (2002) · JAMA · doi:10.1001/jama.287.21.2801 · Cited by 397
Cognitive therapy for psychosis in schizophrenia: An effect size analysis
Gould, R. A., Mueser, K. T., Bolton, E., Mays, V., & Goff, D. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00145-6 · Cited by 389
Cognitive-behavioral therapy for schizophrenia: An empirical review
RECTOR, N. A., & BECK, A. T. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200105000-00002 · Cited by 387
Cognitive-Behavioral Interventions to Reduce Suicide Behavior: A Systematic Review and Meta-Analysis
Tarrier, N., Taylor, K., & Gooding, P. (2008) · Behavior Modification · doi:10.1177/0145445507304728 · Cited by 384
Self-citationSterne, J. A. C., Jüni, P., Schulz, K. F., Altman, D. G., Bartlett, C., & Egger, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1184 · Cited by 382
Lewis, S., Tarrier, N., Haddock, G., Bentall, R., Kinderman, P., Kingdon, D., Siddle, R., Drake, R., Everitt, J., Leadley, K., et al. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.43.s91 · Cited by 373
Self-citationZimmermann, G., Favrod, J., Trieu, V. H., & Pomini, V. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.018 · Cited by 371
Content and quality of 2000 controlled trials in schizophrenia over 50 years
Thornley, B., & Adams, C. (1998) · BMJ · doi:10.1136/bmj.317.7167.1181 · Cited by 364 · cited 1×
“The average number of participants in each trial is relatively small (average 66), but this is the same as for drug trials in schizophrenia over the past 35 years.(35) The measure of trial quality, CTAM, detected methodological variability even in studies that had already passed some methodological inclusion criteria.”
ResultTurkington, D., Kingdon, D., & Turner, T. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.6.523 · Cited by 350
Granholm, E., McQuaid, J. R., McClure, F. S., Auslander, L. A., Perivoliotis, D., Pedrelli, P., Patterson, T., & Jeste, D. V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.520 · Cited by 340
Gøtzsche, P. C. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90017-2 · Cited by 339
Kazdin, A. E., & Bass, D. (1989) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.57.1.138 · Cited by 337 · cited 1×
“In fact, only 2 non-UK studies had a sample size that was above 27 participants per group, which is the smallest sample size likely to identify a modest clinically significant effect.(46) Overall trial quality was significantly higher in UK trials (mean CTAM score: UK 67.”
BackgroundVirtual reality in mental health: A review of the literature
Gregg, L., & Tarrier, N. (2007) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-007-0173-4 · Cited by 304
Self-citationTarrier, N., & Wykes, T. (2004) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.06.020 · Cited by 304 · cited 2×
“A more detailed account with specific scores is given in Tarrier and Wykes.(49)”
MethodSelf-citationCognitive therapy for command hallucinations: randomised controlled trial
Trower, P., Birchwood, M., Meaden, A., Byrne, S., Nelson, A., & Ross, K. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.4.312 · Cited by 268
Measures of effect size for categorical data.
Fleiss, J. L. (1994) · Cited by 248
Training schizophrenics to talk to themselves: A means of developing attentional controls
Meichenbaum, D., & Cameron, R. (1973) · Behavior Therapy · doi:10.1016/s0005-7894(73)80003-6 · Cited by 247
Moja, L. P., Telaro, E., D'Amico, R., Moschetti, I., Coe, L., & Liberati, A. (2005) · BMJ · doi:10.1136/bmj.38414.515938.8f · Cited by 239
Cognitive therapy and recovery from acute psychosis: A controlled trial: 3. Five-year follow-up
Drury, V., Birchwood, M., & Cochrane, R. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.1.8 · Cited by 235
GUMLEY, A., O'GRADY, M., MCNAY, L., REILLY, J., POWER, K., & NORRIE, J. (2003) · Psychological Medicine · doi:10.1017/s0033291703007323 · Cited by 229
Pildal, J., Chan, A.-W., Hróbjartsson, A., Forfang, E., Altman, D. G., & Gøtzsche, P. C. (2005) · BMJ · doi:10.1136/bmj.38414.422650.8f · Cited by 209 · cited 1×
“reviewed had inadequate concealment irrespective of whether they used data in the trial protocol or the trial publication.(93)”
MethodBeck, A. T. (1952) · Psychiatry · doi:10.1080/00332747.1952.11022883 · Cited by 203
The cognitive-behavioural treatment of low self-esteem in psychotic patients: A pilot study
Hall, P. L., & Tarrier, N. (2003) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(02)00013-x · Cited by 194
Self-citationControlled trials: the 1948 watershed
Doll, R. (1998) · BMJ · doi:10.1136/bmj.317.7167.1217 · Cited by 191
Cognitive behavioural therapy for drug‐resistant psychosis
Garety, P. A., Kuipers, L., Fowler, D., Chamberlain, F., & Dunn, G. (1994) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1994.tb01795.x · Cited by 191
Pocock, S. J. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00008-1 · Cited by 184 · cited 1×
“Such trials reflect the scientific method of demonstrating the value of a new treatment in comparison to an appropriate control group by minimizing all possible sources of bias which could render unsafe the conclusion that the new treatment is beneficial.(29) There are established conventions concerning how clinical t…”
BackgroundCognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies
Dickerson, F. B. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00153-x · Cited by 169
Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M., & Slooff, C. J. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.4.324 · Cited by 163
Self-citationHaddock, G., Tarrier, N., Morrison, A. P., Hopkins, R., Drake, R., & Lewis, S. (1999) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050141 · Cited by 159
Self-citationDurham, R. C., Guthrie, M., Morton, R. V., Reid, D. A., Treliving, L. R., Fowler, D., & MacDonald, R. R. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.303 · Cited by 158
Cognitive behavior therapy for persistent auditory hallucinations: From theory to therapy
Bentall, R. P., Haddock, G., & Slade, P. D. (1994) · Behavior Therapy · doi:10.1016/s0005-7894(05)80145-5 · Cited by 152
What are the effects of group cognitive behaviour therapy for voices? A randomised control trial
Wykes, T., Hayward, P., Thomas, N., Green, N. H., Surguladze, S., Fannon, D. G., & Landau, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.03.013 · Cited by 147
Self-citationCognitive therapy for schizophrenia: a preliminary randomized controlled trial
Rector, N. A., Seeman, M. V., & Segal, Z. V. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00308-0 · Cited by 146
Cognitive behavioural group treatment for social anxiety in schizophrenia
Kingsep, P., Nathan, P. R., & Castle, D. J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00376-6 · Cited by 142
Pinto, A., Pia, S. L., Mennella, R., Giorgio, D., & DeSimone, L. (1999) · Psychiatric Services · doi:10.1176/ps.50.7.901 · Cited by 137
Bechdolf, A., Knost, B., Kuntermann, C., Schiller, S., Klosterkötter, J., Hambrecht, M., & Pukrop, R. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00300.x · Cited by 133
Group cognitive-behavioural therapy for schizophrenia: Randomised controlled trial
Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.021386 · Cited by 132 · cited 1×
“In addition, using our own knowledge of work in this area through conference presentations (2004–2006), the Beck psychosis networks, and familiarity with appropriate research groups around the globe, one further trial was added that had been submitted.(40) This study has subsequently been published.”
MethodCase Formulation in Cognitive Behaviour Therapy
(2006) · Routledge eBooks · doi:10.4324/9780203965177 · Cited by 119
Confrontation vs. belief modification in persistently deluded patients
Milton, F., Patwa, V. K., & Hafner, R. J. (1978) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1978.tb02456.x · Cited by 119
Psychodynamic treatment of schizophrenia: is there a future?
Mueser, K. T., & Berenbaum, H. (1990) · Psychological Medicine · doi:10.1017/s003329170001758x · Cited by 119 · cited 1×
“The implementation of CBTp was against a tide of skepticism about the development of psychotherapy for people with psychosis in both countries and specific evidence of poor outcomes.(7) There was also optimism about the likelihood of improved medication now somewhat tempered by the Clinical Antipsychotic Trials in Int…”
BackgroundA pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia
Cather, C., Penn, D. L., Otto, M. W., Yovel, I., Mueser, K. T., & GOFF, D. C. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.002 · Cited by 113
STARTUP, M., JACKSON, M. C., & BENDIX, S. (2004) · Psychological Medicine · doi:10.1017/s0033291703001211 · Cited by 111
A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia
Halperin, S., Nathan, P., Drummond, P., & Castle, D. (2000) · Australian and New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00820.x · Cited by 110
Tarrier, N., & Calam, R. (2002) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465802003065 · Cited by 109
Self-citationAre randomised controlled trials the only gold that glitters?
Slade, M., & Priebe, S. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.4.286 · Cited by 101 · cited 1×
“Individual CBTp 27 (24) 19 (1) 12 (2) 12 (0) 3 (0) 0 (0) 27 Group CBTp 5 (4) 4 (1) 3 (0) 3 (0) 1 (0) 2 (2) 7 Total 32 ( 28 ) 23 (2) 15 (2) 15 (0) 4 (0) 2 (2) 34”
Statistical Aspects of the Design and Analysis of Clinical Trials
Everitt, B. S., & Pickles, A. (2000) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860943843 · Cited by 97
Self-citationREDUCING DELUSIONAL SPEECH IN CHRONIC, PARANOID SCHIZOPHRENICS1
Liberman, R. P., Teigen, J. R., Patterson, R. L., & Baker, V. (1973) · Journal of Applied Behavior Analysis · doi:10.1901/jaba.1973.6-57 · Cited by 90 · cited 2×
“Target symptom 0.400 0.252, 0.548 74.1 (32), significant at the 5% level 33 1964 Positive symptoms 0.372 0.228, 0.516 61.7 (31), significant at the 5% level 32 1918 Negative symptoms 0.437 0.171, 0.704 118.1 (22), significant at the 5% level 23 1268 Functioning 0.378 0.154, 0.602 36.7 (14), significant at the 5% level…”
MethodInfluentialGreenfield, S. A. (2002) · The British Journal of Psychiatry · doi:10.1017/s0007125000161768 · Cited by 80
Evidence-based psychotherapeutic interventions in the community care of schizophrenia
Thornicroft, G., & Susser, E. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.1.2 · Cited by 75 · cited 1×
“Target symptom 0.400 0.252, 0.548 74.1 (32), significant at the 5% level 33 1964 Positive symptoms 0.372 0.228, 0.516 61.7 (31), significant at the 5% level 32 1918 Negative symptoms 0.437 0.171, 0.704 118.1 (22), significant at the 5% level 23 1268 Functioning 0.378 0.154, 0.602 36.7 ( 14 ), significant at the 5% lev…”
InfluentialHallucination focused integrative treatment improves quality of life in schizophrenia patients
Wiersma, D., Jenner, J. A., Nienhuis, F. J., & van, D. W. G. (2004) · Acta Psychiatrica Scandinavica · doi:10.1046/j.0001-690x.2003.00237.x · Cited by 56
The dissemination of innovative cognitive-behavioural psychosocial treatments for schizophrenia
Tarrier, C. B. (1999) · Journal of Mental Health · doi:10.1080/09638239917049 · Cited by 54
Granholm, E. L., McQuaid, J. R., McClure, F. S., Pedrelli, P., & Jeste, D. V. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00186-9 · Cited by 53
Allocation Concealment in Clinical Trials
Schulz, K. F., Altman, D. G., & Moher, D. (2002) · JAMA · doi:10.1001/jama.288.19.2406-jlt1120-4-1 · Cited by 51
Marneros, A. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.024257 · Cited by 51
Everitt, B. S., & Wessely, S. (2007) · Wiley eBooks · doi:10.1002/9780470723852 · Cited by 50
Self-citationCOGNITIVE THERAPY IN EARLY PSYCHOSIS: A PILOT RANDOMIZED CONTROLLED TRIAL
Jolley, S., Garety, P., Craig, T., Dunn, G., White, J., & Aitken, M. (2003) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465803004107 · Cited by 47
Daniels, L. (1998) · PubMed · Cited by 45
Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know
Meltzer, H. Y., & Bobo, W. V. (2006) · CNS Spectrums · doi:10.1017/s109285290002664x · Cited by 42
A Preliminary Experiment on Paranoid Delusions
Shapiro, M. B., & Ravenette, A. T. (1959) · Journal of Mental Science · doi:10.1192/bjp.105.439.295 · Cited by 39 · cited 6×
“Individual CBTp 27 (24) 19 (1) 12 ( 2 ) 12 (0) 3 (0) 0 (0) 27 Group CBTp 5 (4) 4 (1) 3 (0) 3 (0) 1 (0) 2 (2) 7 Total 32 (28) 23 (2) 15 (2) 15 (0) 4 (0) 2 (2) 34”
MethodInfluentialMeasurement of quality of primary studies for meta-analysis.
Brown, S. A. (1991) · PubMed · Cited by 39
Cognitive Group Therapy for Paranoid Schizophrenics: Applying Cognitive Dissonance
Levine, J., Barak, Y., & Granek, I. (1998) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.12.1.3 · Cited by 36
GAUDIANO, B. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200601000-00003 · Cited by 32
Modern Medical Statistics: A Practical Guide
Everitt, B. J. (2003) · Cited by 28
Self-citationUpdate on Cognitive Behavioral Psychotherapy for Schizophrenia: Review of Recent Studies
Dickerson, F. (2004) · Journal of Cognitive Psychotherapy · doi:10.1891/jcop.18.3.189.65654 · Cited by 25
The Effectiveness of Cognitive Therapy for Schizophrenia: What Can We Learn from the Meta-Analyses?
Sensky, T. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000083997 · Cited by 23 · cited 1×
“Target symptom 0.400 0.252, 0.548 74.1 (32), significant at the 5% level 33 1964 Positive symptoms 0.372 0.228, 0.516 61.7 (31), significant at the 5% level 32 1918 Negative symptoms 0.437 0.171, 0.704 118.1 ( 22 ), significant at the 5% level 23 1268 Functioning 0.378 0.154, 0.602 36.7 (14), significant at the 5% lev…”
InfluentialReflections on methodological issues in mental health research
Richardson, A. (2000) · Journal of Mental Health · doi:10.1080/09638230020005192 · Cited by 19
Bailer, J., Takats, I., & Westermeier, C. (2001) · Zeitschrift für Klinische Psychologie und Psychotherapie · doi:10.1026/0084-5345.30.4.268 · Cited by 16
Research works printed but not linked: 1
- [24]NICE Schizophrenia: Core interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care 2003 20704054
Cited by
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
Mindfulness-based therapy: a comprehensive meta-analysis
Khoury, B., Lecomte, T., Fortin, G., Masse, M., Therien, P., Bouchard, V., Chapleau, M.-A., Paquin, K., & Hofmann, S. G. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.05.005 · Cited by 2,003
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
“, average Clinical Trial Assessment Measure scores for CBT for psychosis [29] and cognitive remediation).”
BackgroundSelf-citationGalletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
“Although positive symptoms were the initial targets of CBTp, research has also been conducted using CBTp for negative symptoms and for comorbid depression, anxiety and substance use (Wykes et al., 2008).”
Background
Metadata
- Authors
- Wykes, T., Steel, C., Everitt, B., & Tarrier, N.
- Affiliations
- King's College London (GB)
- University of Manchester (GB)
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-04
- Volume
- 34
- Issue
- 3
- Pages
- 523-537
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC2632426
- OpenAlex
- W2140526915
- Cited by
- 1,029
- References
- 98
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 29 · 2023: 39 · 2022: 42 · 2021: 39 · 2020: 38 · 2019: 64 · 2018: 59 · 2017: 62 · 2016: 76 · 2015: 73 · 2014: 91 · 2013: 96 · 2012: 87
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Assessments
- Keywords
- schizophrenia
- MeSH terms
- Humans, Psychometrics, Schizophrenia, Cognitive Behavioral Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.